Lytix Biopharma is a clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer. Lead compound, LTX-315, induces polyclonal T cell response using the patient’s own tumor as source of antigens to generate a personal immune response.

LTX-315’s ability to enhance T cell infiltration in the patient’s tumors makes it ideal for combination therapies.